InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,638.61
(
0.67%
)
Post# of 252200
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 74
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: RockRat post# 223123

Saturday, 01/12/2019 4:06:46 PM

Saturday, January 12, 2019 4:06:46 PM

Post# of 252200
JNCE:

From the reading I did, I *could* make a case for CTLA-4. However, it appears that CTLA-4 antagonism upregulates ICOS. So if a cell needs to be responsive to CTLA-4 blockade to upregulate ICOS, then what strong need is there for JNCE's drug? It becomes a small, incremental addition to the response rather than an independent driver for a response.

Meh.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up